Background T cells engineered to express Chimeric Antigen Receptors (CAR T cells) have shown impressive clinical success for patients with B cell malignancies. However, since CAR T cells are self-replicating living drugs it is difficult to regulate their function after administration to a patient, often resulting in severe side effects such as cytokine release syndrome … Continue reading Christian Doppler Laboratory